🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the effort against superbug strains of the infection, according to health experts.

An International Challenge

Cases of gonorrhoea are escalating worldwide, with estimates suggesting more than 82 million new cases annually. Especially elevated rates are reported in the African continent and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the context of growing infection rates, escalating drug resistance and the highly restricted treatment choices presently on offer.”

Medical experts are deeply concerned about the increase in antibiotic-resistant strains. The World Health Organization has designated it as a "priority pathogen". Ongoing monitoring found that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Secure Clearance

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US FDA in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Experts anticipate that specific application of this new drug will help slow the spread of drug resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, gained clearance in close succession. This treatment, which is also used to treat urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to develop it.

“This approval signifies a major breakthrough in the management of highly resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Clinical Trial Results and Worldwide Availability

According to data published in a prominent scientific publication, zoliflodacin eradicated more than 90% of genital gonorrhoea infections. This puts it on an similar efficacy with the existing first-line therapy, which combines two antibiotics. The research included over 900 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the rights to register and commercialise the drug in many low-income and middle-income countries.

Clinicians treating patients have expressed hope. The availability of a easy-to-administer therapy like this is hailed as a "revolutionary step" for gonorrhoea control. This is considered crucial to lessen the impact of the illness for people and to stop the proliferation of extremely resistant gonorrhoea worldwide.